Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist

Brain Research

Volumn 980, Issue 2, 2003, Pages 206-212

  Valdez, Glenn R ^a   Zorrilla, Eric P ^a   Rivier, Jean ^b   Vale, Wylie W ^b   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Anxiety; CRF; CRF2 receptor; Locomotor activity; Stress; Urocortin 3

Indexed keywords

ANXIOLYTIC AGENT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR 2; CORTICOTROPIN RELEASING FACTOR RECEPTOR; PROTEIN SUBUNIT; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG; UROCORTIN; UROCORTIN III;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HYPOTHESIS; INJECTION; LOCOMOTION; MALE; MAZE TEST; MODULATION; MONITORING; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; REDUCTION; REGULATORY MECHANISM; STRESS; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

EID: 0038303469     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02971-8     Document Type: Article

References (44)

1. Andrews N., File S.E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur. J. Pharmacol. 235:1993;109-112.
2. Arase K., York D.A., Shimizu H., Shargill N., Bray G.A. Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. Am. J. Physiol. 255:1988;E255-259.
3. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., Koob G.F., Vale W.W., Lee K.F. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genet. 24:2000;410-414.
4. Bittencourt J.C., Vaughn J., Arias C., Rissman R.A., Vale W.W., Sawchenko P.E. Urocortin expression in rat brain: Evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. J. Comp. Neurol. 415:1999;285-312.
5. Britton K.T., Lee G., Dana R., Risch S.C., Koob G.F. Activating and 'anxiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. Life Sci. 39:1986;1281-1286.
6. Britton K.T., Morgan J., Rivier J., Vale W., Koob G.F. Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology. 86:1985;170-174.
7. Casada J.H., Dafny N. Restraint and stimulation of bed nucleus of the stria terminalis produce similar stress-like behaviors. Brain Res. Bull. 27:1991;207-212.
8. Cole B.J., Koob G.F. Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor. J. Pharmacol. Exp. Ther. 247:1988;902-910.
9. Contarino A., Dellu F., Koob G.F., Smith G.W., Lee K.F., Vale W., Gold L.H. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 835:1999;1-9.
10. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49:1994;171-176.
11. Deroche V., Piazza P.V., Casolini P., Maccari S., Le Moal M., Simon H. Stress-induced sensitization to amphetamine and morphine psychomotor effects depend on stress-induced corticosterone secretion. Brain Res. 598:1992;343-348.
12. Dunn A.J., Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 15:1990;71-100.
13. Ehlers C.L., Indik J.H., Koob G.F., Bloom F.E. The effect of single and repeated electroconvulsive shock (ECS) on locomotor activity in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry. 7:1983;217-222.
14. Gewirtz J.C., McNish K.A., Davis M. Lesions of the bed nucleus of the stria terminalis block sensitization of the acoustic startle reflex produced by repeated stress, but not fear-potentiated startle. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;625-648.
15. Hatalski C.G., Guirguis C., Baram T.Z. Corticotropin releasing factor mRNA expression in the hypothalamic paraventricular nucleus and the central nucleus of the amygdala is modulated by repeated acute stress in the immature rat. J. Neuroendocrinol. 10:1998;663-669.
16. Ho S.P., Takahashi L.K., Livanov V., Spencer K., Lesher T., Maciag C., Smith M.A., Rohrbach K.W., Hartig P.R., Arneric S.P. Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Mol. Brain Res. 89:2001;29-40.
17. Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Med. 7:2001;605-611.
18. Inoue K., Valdez G.R., Reyes T.M., Reinhardt L.E., Tabarin A., Rivier J., Vale W.W., Sawchenko P.E., Koob G.F., Zorrilla E.P. Human urocortin 2, a selective agonist for the type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat. J. Pharmacol. Exp. Ther. 305:2003;385-393.
19. Kishimoto T., Radulovic J., Radulovic M., Lin C.R., Schrick C., Hooshmand F., Hermanson O., Rosenfeld M.G., Spiess J. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nature Genet. 24:2000;415-419.
20. Koob G.F., Heinrichs S.C. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. 848:1999;141-152.
21. Koob G.F., Heinrichs S.C., Menzaghi F., Pich E.M., Britton K.T. Corticotropin releasing factor, stress, and behavior. Semin. Neurosci. 6:1994;221-229.
22. Koob G.F., Swerdlow N., Seeligson M., Eaves M., Sutton R., Rivier J., Vale W. Effects of alpha-flupenthixol and naloxone on CRF-induced locomotor activation. Neuroendocrinology. 39:1984;459-464.
23. Krahn D.D., Gosnell B.A., Grace M., Levine A.S. CRF antagonist partially reverses CRF- and stress-induced effects on feeding. Brain Res. Bull. 17:1986;285-289.
24. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., Vaughan J., Reyes T.M., Gulyas J., Fischer W., Bilezikjian L., Rivier J., Sawchenko P.E., Vale W.W. Identification of urocortin 3, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. USA. 98:2001;7570-7575.
25. Li C., Vaughan J., Sawchenko P.E., Vale W.W. Urocortin 3-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J. Neurosci. 22:2002;991-1001.
26. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. USA. 92:1995;836-840.
27. Menard J., Treit D. Lateral and medial septal lesions reduce anxiety in the plus-maze and probe-burying tests. Physiol. Behav. 60:1996;845-853.
28. Möller C., Wiklund L., Sommer W., Thorsell A., Heilig M. Decreased experimental anxiety and voluntary ethanol consumption in rats following central but not basolateral amygdala lesions. Brain Res. 760:1997;94-101.
29. Pellegrino L.J., Pellegrino A.S., Cushman A.J. A Sterotaxic Atlas of the Rat Brain. 1979;Plenum Press, New York.
30. Perrin M.H., Vale W.W. Corticotropin releasing factor receptors and their ligand family. Ann. NY Acad. Sci. 885:1999;312-328.
31. Radulovic J., Ruhmann A., Liepold T., Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J. Neurosci. 19:1999;5016-5025.
32. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., Hogenesch J.B., Gulyas J., Rivier J., Vale W.W., Sawchenko P.E. Urocortin 2: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. USA. 98:2001;2843-2848.
33. Spina M., Merlo-Pich E., Chan R.K., Basso A.M., Rivier J., Vale W., Koob G.F. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science. 273:1996;1561-1564.
34. Spina M.G., Merlo-Pich E., Akwa Y., Balducci C., Basso A.M., Zorrilla E.P., Britton K.T., Rivier J., Vale W.W., Koob G.F. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology (Berl.). 160:2002;113-121.
35. Stohr T., Almeida O.F., Landgraf R., Shippenberg T.S., Holsboer F., Spanagel R. Stress- and corticosteroid-induced modulation of the locomotor response to morphine in rats. Behav. Brain Res. 103:1999;85-93.
36. Sutton R.E., Koob G.F., Le Moal M., Rivier J., Vale W. Corticotropin releasing factor produces behavioural activation in rats. Nature. 297:1982;331-333.
37. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nature Genet. 19:1998;162-166.
38. Valdez G.R., Inoue K., Koob G.F., Rivier J., Vale W.W., Zorrilla E.P. Human urocortin 2: Mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res. 943:2002;142-150.
39. Vale W., Rivier C., Brown M.R., Spiess J., Koob G., Swanson L., Bilezikjian L., Bloom F., Rivier J. Chemical and biological characterization of corticotropin releasing factor. Recent Prog. Horm. Res. 39:1983;245-270.
40. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397.
41. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., Prins G.S., Perrin M., Vale W., Sawchenko P.E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 428:2000;191-212.
42. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., Chan R., Turnbull A.V., Lovejoy D., Rivier C., Rivier J., Sawchenko P.E., Vale W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 378:1995;287-292.
43. Yadin E., Thomas E., Grishkat H.L., Strickland C.E. The role of the lateral septum in anxiolysis. Physiol. Behav. 53:1993;1077-1083.
44. Zorrilla E.P., Valdez G.R., Nozulak J., Koob G.F., Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. 952:2002;188-199.